Technophage announces FDA Fast Track Designation Granted to TP-102  for the treatment of patients with infected diabetic foot ulcers caused by Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumannii

Technophage announces FDA Fast Track Designation Granted to TP-102  for the treatment of patients with infected diabetic foot ulcers caused by Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumannii

14 Mai 2021 | Press release

Technophage announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TP-102, the company’s first bacteriophage cocktail, for the treatment of infected diabetic foot ulcers caused by three different bacteria (Pseudomonas...
Interview to Link to Leaders by Miguel Garcia, CEO of Technophage

Interview to Link to Leaders by Miguel Garcia, CEO of Technophage

11 Mai 2021 | News

In the past few months, and due to the recently initiated Phase I/IIa Clinical Trial of the bacteriophage cocktail TP-102, which has been entirely developed in the company for the treatment of diabetic foot ulcers infected by Pseudomonas aeruginosa, Acinetobacter...
Technophage is hiring a Head of Neurosciences

Technophage is hiring a Head of Neurosciences

3 Mai 2021 | Careers

TechnoPhage is hiring a Head of Neurosciences with a strong scientific background to lead a team dedicated to the research and development of new medicines in the Neurosciences and Ophthalmology therapeutic areas.  Main responsibilities: Research and development of...
Technophage featured at TV show ‘Exame Informática’

Technophage featured at TV show ‘Exame Informática’

27 Abr 2021 | News

Technophage has been recently featured in the TV show ‘Exame Informática’. In this piece, you can quickly learn a bit more about our bacteriophage cocktail TP-102, also gaining an opportunity to a virtual tour of our GMP production unit. TechnoPhage...